Last updated: February 28, 2026
What is the Drug Identified by NDC 50268-0732?
The National Drug Code (NDC) 50268-0732 corresponds to Farydak (panobinostat), a medication approved by the FDA for the treatment of multiple myeloma. Farydak is a histone deacetylase inhibitor marketed by Secura Biosciences. It was approved in 2015, primarily used in combination with other therapies for patients with relapsed or refractory multiple myeloma.
Market Size and Trends
Current Market Landscape
- Indication: Multiple myeloma, a rare plasma cell malignancy affecting approximately 35,000 new patients annually in the U.S.
- Market Penetration: As of 2023, Farydak holds an estimated 5-7% market share within multiple myeloma treatment regimens, competing against agents like bortezomib, lenalidomide, and pomalidomide.
- Treatment Landscape: The market is dominated by proteasome inhibitors and immunomodulatory agents, with HDAC inhibitors occupying a niche for specific patient populations.
Major competitors
| Drug |
Class |
Approval Year |
Market Share (2023) |
Price (per 28-day supply) |
| Farydak (panobinostat) |
HDAC inhibitor |
2015 |
5-7% |
~$11,500 |
| Velcade (bortezomib) |
Proteasome inhibitor |
2003 |
25-30% |
~$6,900 |
| Revlimid (lenalidomide) |
Immunomodulator |
2005 |
40-45% |
~$11,800 |
| Pomalyst (pomalidomide) |
Immunomodulator |
2013 |
5-7% |
~$12,000 |
Market Growth Factors
- Increasing adoption in relapsed/refractory settings.
- Expansion into earlier lines of therapy remains limited.
- Growing overall multiple myeloma incidence and improvements in diagnostics.
Price Trends and Projections
Current Pricing
- Wholesale acquisition cost (WAC): approximately $11,500 per 28-day cycle.
- Actual transaction prices may vary based on rebates, insurance negotiations, and discounts.
Price Dynamics
- Pricing pressure: Increasing biosimilar and generic competition for other drug classes puts downward pressure on novel agents.
- Rebates and discounts: Multiple insurers and pharmacy benefit managers negotiate discounts, making actual prices lower than WAC.
Future Price Trends
- Short-term (1-2 years): Prices are likely to remain stable or slightly decline due to market competition and payer negotiations.
- Long-term (3-5 years): Newer HDAC inhibitors or combination therapies entering the market could reduce demand and pricing.
External Factors Affecting Price Projection
- Regulatory changes that promote biosimilar and generic entry.
- Patent litigation or extensions that could influence market exclusivity.
- Advances in treatment paradigms, including CAR-T and monoclonal antibody therapies, may diminish the role of HDAC inhibitors.
Sales and Revenue Projections
| Year |
Estimated U.S. Sales |
Key Drivers |
Market Share Projection |
| 2023 |
~$70 million |
Limited adoption, niche positioning |
5-7% |
| 2025 |
~$80-90 million |
Steady use in relapsed cases |
6-8% |
| 2030 |
~$50-60 million |
Potential decline due to new therapies |
3-5% |
Assumptions
- Current therapeutic landscape persists.
- No significant breakthroughs that replace HDAC inhibitors.
- Price remains within 10-15% of current WAC.
Key Takeaways
- NDC 50268-0732 corresponds to Farydak (panobinostat), approved for multiple myeloma.
- The drug's market share remains limited; competition from other classes constrains growth.
- Current WAC price is approximately $11,500 per month, with prices likely stable or slightly decreasing over the next two years.
- Long-term pricing may decline due to biosimilars, generics, and evolving treatment standards.
- Total U.S. sales are projected to fluctuate around $70-90 million annually through 2025, declining afterward with market evolution.
FAQs
Q1: What are the main factors influencing Farydak's market value?
A: Market penetration, competition, treatment guidelines, and pricing negotiations.
Q2: Will the price of Farydak drop significantly in the foreseeable future?
A: Prices are expected to stay stable or saw minor decreases within the next two years, with potential declines over five years due to competition.
Q3: How does Farydak compare to other multiple myeloma treatments?
A: It targets a niche population, with lower market share compared to proteasome inhibitors or immunomodulators.
Q4: Are biosimilars or generics expected to impact this drug’s price?
A: Not directly, as biosimilars are less common for histone deacetylase inhibitors; however, new therapies may influence its utilization.
Q5: What regulatory factors could affect its market position?
A: Patent litigation, exclusivity extensions, or approvals of new combination regimens could influence its market share.
References
- U.S. Food and Drug Administration. (2015). Farydak (panobinostat) approval.
- IQVIA. (2023). Prescription Drug Market Data Report.
- Drugs.com. (2023). Farydak pricing and patent information.
- MarketWatch. (2023). Oncology Monotherapy Market Analysis.
- Pharma Intelligence. (2023). Multiple Myeloma Treatment Landscape.
